RxDoctor Payments Data

Jose Ibarra, MD

Family Medicine · Fresno, CANPI 1063481331

Payments from drug & device makers

$1,301in general payments, 2019–2025

Across 71 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$664
  • Lilly USA, LLC$325
  • Amgen$174
  • GSK$49
  • Merz North America, Inc.$22
  • Exact Sciences$20
  • plus $47 from 3 others

What the payments were for

  • Food & beverage$1,301100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk46$664
Lilly USA, LLC13$325
Amgen4$174
GSK3$49
Merz North America, Inc.1$22
Exact Sciences1$20
CMP Pharma, Inc.1$17
Merck1$17
Sanofi-aventis U.S. LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,301 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$7,609
Medicare patients
28
Services billed
71

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin87$86,820
OzempicSemaglutide66$68,491
RybelsusSemaglutide39$61,603
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$15,419
EliquisApixaban13$11,816
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$4,130
Humalog Kwikpen U-100Insulin Lispro25$3,688
Atorvastatin Calcium383$3,349
Celecoxib63$3,010
Tamsulosin Hcl104$1,167
Metformin Hcl219$1,141
Levothyroxine Sodium64$901
Omeprazole137$862
Glipizide102$835
Lisinopril127$728

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$664$130,093105 claims
GSKTrelegy Ellipta$49$15,41921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →